Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis

Ying He, Sze Wan Hung, Bo Liang, Ruizhe Zhang, Yating Gao, Ching Yan Chu, Tao Zhang, Hui Xu, Jacqueline Pui Wah Chung, Chi Chiu Wang
Frontiers in immunology · 2025 · vol. 16 , pp. 1741271 · doi:10.3389/fimmu.2025.1741271 · PMID:41368639 · PMC12683330
other OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study identified the receptor tyrosine kinase inhibitor sunitinib as a novel immunotherapy that inhibits myeloid-derived suppressor cells for endometriosis treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

[This corrects the article DOI: 10.3389/fimmu.2021.641206.].

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-06-04T00:30:46.950704+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine